Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.
Oct 2026· Annals of Oncology· 1 citation· 25 references
Medicine
TL;DR
Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.
Abstract
Background
Ribociclib plus nonsteroidal aromatase inhibitor (NSAI) demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at the primary efficacy analysis of the phase 3 NATALEE trial. This prespecified 6-year analysis assessed overall survival (OS) and other efficacy outcomes as well as safety.
PATIENTS AND
Methods
Eligible patients were adults with HR+/HER2- EBC and anatomic stage IIA (N1 or N0 with high-risk factors), IIB, or III disease. Enrolled patients were randomized 1:1 to ribociclib 400 mg/day (3 weeks on/1 week off for 3 years) plus NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 5 years) or NSAI alone. Premenopausal women and men also received goserelin. The primary endpoint was iDFS, and secondary/exploratory endpoints included OS, distant disease-free survival (DDFS), and distant recurrence-free survival (DRFS).
Results
With a median OS follow-up of 66.5 months, ribociclib plus NSAI demonstrated an OS benefit over NSAI alone (6-year ΔOS, 2.1%; HR, 0.809 [95% CI: 0.661-0.989]; nominal 1-sided P = .019), which was generally consistent across key subgroups. An increasing iDFS benefit with ribociclib plus NSAI was also observed (6-year ΔiDFS, 5.3%; HR, 0.741 [95% CI: 0.646-0.849]; nominal 1-sided P < .0001), which was also generally consistent across key subgroups. DDFS (HR, 0.744 [95% CI: 0.646-0.858]) and DRFS (HR, 0.738 [95% CI: 0.634-0.858]) results supported these findings. No new safety signals were observed.
Conclusions
This prespecified descriptive 6-year OS analysis demonstrated positive OS results with a clinically relevant benefit of ribociclib plus NSAI, consistent with the increasing reduction in recurrence risk. These results reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.
CLINICAL TRIAL REGISTRATION
NCT03701334 (ClinicalTrials.gov).
BACKGROUND
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have transformed the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Ribociclib plus an aromatase inhibitor (AI) was approved in Canada as adjuvant treatment for high-risk stage II-III ea...
D. Soliman, C. Brezden-Masley, S. Sehdev et al.· PharmacoEconomics - Open· 0 citations
Aim: Ribociclib and abemaciclib, cyclin-dependent kinase 4/6 inhibitors, are adjuvant treatments for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). In the Phase III NATALEE trial, ribociclib plus an aromatase inhibitor (AI) significantly improved in...
D. Soliman, C. Brezden-Masley, S. Sehdev et al.· Journal of Comparative Effec...· 0 citations
The addition of entinostat, a histone deacetylase inhibitor, to exemestane has demonstrated improved progression-free survival (PFS) in hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) following endocrine therapy failure in the EOC103A3101 randomi...
Jia-Ni Wang, Qing-Yuan Zhang, Xi-Chun Hu et al.· Signal Transduction and Targ...· 0 citations
Background: This study evaluates the real-world effectiveness, safety, and tolerability of adjuvant abemaciclib or ribociclib combined with a non-steroidal aromatase inhibitor (NSAI) in high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer in Western In...
Kajal Shah, H. Panchal, Apurva Patel et al.· Cureus· 0 citations
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression. Platinum agents such as carboplatin have been incorporated into neoadjuvant regimens to improve pathological complete response (pCR)...
Samira Merah, Amal Kouchkar, A. Ladjeroud et al.· Archives of Breast Cancer· 0 citations